Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2022 | Promising treatments under investigation in Waldenström’s macroglobulinemia

Jorge Castillo • 15 Jun 2022

EHA 2022

Rare Diseases Waldenström’s Macroglobulinemia Acalabrutinib Antibodies Bendamustine CAR-T CLR 131 Loncastuximab tesirine Nemtabrutinib Pirtobrutinib Rituximab Venetoclax Zanubrutinib

Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on promising therapies that are being developed for the treatment of Waldenström’s macroglobulinemia (WM), including fixed-duration triplet regimens, BTK inhibitor combination strategies, CLR 131, loncastuximab tesirine, and CAR-T therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consulting fees and/or research funds from Abbvie, AstraZeneca, BeiGene, Cellectar, Janssen, Pharmacyclics, Roche, TG Therapeutics.

Real-world outcomes following dose reduction of first-line ibrutinib in patients with WM

Jorge Castillo • 10 Dec 2023

Acalabrutinib plus rituximab for treating anti-MAG mediated IgM peripheral neuropathy in WM

Jorge Castillo • 10 Dec 2023

Outcomes following venetoclax monotherapy in patients with R/R WM in the real-world setting

Jorge Castillo • 10 Dec 2023

Research updates in WM from ASH 2023

Jorge Castillo • 10 Dec 2023

Related Videos

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

Personalized risk assessment for transplantation in primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Hematological manifestations associated with primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024